Given the high structural similarity between the antimalarials Cyc and Pyr (Figure 1a) and the recent evidence highlighting Pyr’s anti-cancer properties stem from functional inhibition of human DHFR [4], Cyc and its triazine analogues were analyzed to determine if they may interact with human DHFR using molecular docking. The gene discussed is DHFR; the disease is cancer.